LCAT Human
Description
Product Specs
Product Science Overview
LCAT is a member of the phospholipid:diacylglycerol acyltransferases family. It is primarily bound to HDL particles in the blood plasma, where it catalyzes the transfer of fatty acids from lecithin (phosphatidylcholine) to free cholesterol, forming cholesteryl ester and lysolecithin . This reaction is critical for the conversion of nascent discoidal HDL particles into mature spherical HDL particles, which are more efficient in cholesterol transport.
LCAT deficiency can lead to several health issues, including impaired vision due to cholesterol corneal opacities, anemia, and kidney damage . The enzyme’s role in HDL metabolism and RCT makes it a potential therapeutic target for cardiovascular diseases, particularly atherosclerosis. Increasing LCAT activity has been shown to enhance HDL functionality and promote cholesterol efflux from macrophages, reducing the risk of plaque formation in arteries .
Recombinant human LCAT (rhLCAT) has been developed to study its therapeutic potential. In clinical studies, rhLCAT has demonstrated the ability to increase HDL cholesterol levels and improve HDL functionality. For instance, in a Phase 2a study, multiple ascending doses of rhLCAT (MEDI6012) were administered to patients with stable atherosclerosis. The results showed significant dose-related increases in HDL cholesterol, HDL cholesterol ester, and total cholesterol ester levels . Additionally, rhLCAT has been shown to rescue defective HDL-mediated endothelial protection in patients with acute coronary syndrome, suggesting its potential in restoring HDL functionality and promoting vascular health .
Ongoing research aims to further understand the mechanisms by which LCAT influences lipid metabolism and to explore its therapeutic applications. Studies have shown that rhLCAT can restore HDL-mediated nitric oxide production in endothelial cells, which is crucial for maintaining vascular tone and preventing inflammation . These findings highlight the enzyme’s potential in treating cardiovascular diseases and improving overall cardiovascular health.
In conclusion, Lecithin-Cholesterol Acyltransferase (Human Recombinant) is a vital enzyme in lipid metabolism with significant therapeutic potential. Its role in HDL maturation and reverse cholesterol transport makes it a promising target for cardiovascular disease treatment and prevention.
